List of Triesence drug patents

Triesence is owned by Novartis.

Triesence contains Triamcinolone Acetonide.

Triesence has a total of 2 drug patents out of which 0 drug patents have expired.

Triesence was authorised for market use on 29 November, 2007.

Triesence is available in injectable;intravitreal dosage forms.

Triesence can be used as visualization during vitrectomy procedures; treatment of ophthalmic disorders.

The generics of Triesence are possible to be released after 17 December, 2029.

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8211880 NOVARTIS Low viscosity, highly flocculated triamcinolone acetonide suspensions for intravitreal injection
Mar, 2029

(5 years from now)

US8128960 NOVARTIS Low viscosity, highly flocculated triamcinolone acetonide suspensions for intravitreal injection
Dec, 2029

(6 years from now)

Drugs and Companies using TRIAMCINOLONE ACETONIDE ingredient

Market Authorisation Date: 29 November, 2007

Treatment: Visualization during vitrectomy procedures; Treatment of ophthalmic disorders

Dosage: INJECTABLE;INTRAVITREAL

More Information on Dosage

TRIESENCE family patents

5

United States

1

South Africa

1

Denmark

1

Mexico

1

Australia

1

Hong Kong

1

Slovenia

1

Russia

1

Uruguay

1

Argentina

1

Brazil

1

Portugal

1

Spain

1

Korea, Republic of

1

Poland

1

Chile

1

Taiwan, Province of China

1

China

1

Japan

1

Canada

1

European Union

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic

Other things you might be interested in